{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:15:13Z","timestamp":1720779313021},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1446","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T16:01:59Z","timestamp":1565712119000},"page":"S95-S115","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires pneumologiques"],"prefix":"10.1016","volume":"98","author":[{"given":"Philippe","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1446_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","article-title":"Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab","volume":"27","author":"Sandler","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0020","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1446_bib0025","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/annonc\/mdp590","article-title":"Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors","volume":"21","author":"Barlesi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0030","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1446_bib0035","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0040","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1684\/bdc.2011.1446_bib0045","first-page":"1567","article-title":"Bronchoscopic aspects of renal cell carcinoma (RCC)","volume":"19","author":"Dobbertin","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1684\/bdc.2011.1446_bib0050","unstructured":"Cancer therapy evaluation program, common terminology criteria for adverse events, V4.02 t\u00e9l\u00e9charg\u00e9 le 18 mars 2010 (http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.02_2009-09-15_QuickReference_8.5\u00d711.pdf)."},{"key":"10.1684\/bdc.2011.1446_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1465-9921-8-11","article-title":"An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral centre","volume":"8","author":"Fartoukh","year":"2007","journal-title":"Respir Res"},{"key":"10.1684\/bdc.2011.1446_bib0060","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.athoracsur.2009.06.011","article-title":"Surgical lung resection for severe hemoptysis","volume":"88","author":"Andrejak","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1684\/bdc.2011.1446_bib0065","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1378\/chest.09-0780","article-title":"Diffuse alveolar hemorrhage induced by everolimus","volume":"137","author":"Vandewiele","year":"2010","journal-title":"Chest"},{"key":"10.1684\/bdc.2011.1446_bib0070","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","article-title":"Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)","volume":"4","author":"White","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1592\/phco.29.4.473","article-title":"Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature","volume":"29","author":"Wong","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1684\/bdc.2011.1446_bib0080","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1469-0691.2010.03143.x","article-title":"Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after prophylaxis discontinuation: a case control-study","volume":"16","author":"De Castro","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1684\/bdc.2011.1446_bib0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/TP.0b013e3181aad256","article-title":"Analysis of USRDS: incidence and risk factors for Pneumocystis jirovecii pneumonia","volume":"88","author":"Neff","year":"2009","journal-title":"Transplantation"},{"key":"10.1684\/bdc.2011.1446_bib0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1446_bib0095","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0100","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1446_bib0105","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0110","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0115","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2011.1446_bib0120","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0125","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0130","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0135","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1446_bib0145","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2011.1446_bib0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.coc.0000258732.80710.05","article-title":"Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer","volume":"30","author":"Bukowski","year":"2007","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10.1684\/bdc.2011.1446_bib0155","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1446_bib0165","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2009.10.007","article-title":"Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event","volume":"67","author":"Ide","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2011.1446_bib0180","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0185","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1446_bib0190","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"\u00c0 phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1446_bib0195","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Non-infectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1684\/bdc.2011.1446_bib0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","article-title":"Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients","volume":"144","author":"Champion","year":"2006","journal-title":"Ann Intern Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T04:35:30Z","timestamp":1602477330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305294"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1446","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}